Company: GLPG
Filing Date: 2025-03-27
Form Type: 20-F
Source: 0001558370-25-003806
Chunk: 476

Company: GALAPAGOS NV
Filing Date: 2025-03-27
Form: 20-F
Item: Item 19
Chunk 476
---
 ​   ​       ​          ​   ​       ​          ​   €        104,571   ​   ​       ​       ​   ​       ​       ​   ​       10,698    ​   €    115,270
​                                                                                                           ​   ​       ​          ​   ​       ​          ​   ​              ​   ​   ​       ​       ​   ​       ​       ​   ​       ​         ​   ​    ​      
Cash used in operating activities for other liabilities related to the acquisition of subsidiaries (2022)   ​   ​       ​          ​   ​       ​          ​   €         28,164   ​   ​       ​       ​   ​       ​       ​   ​       ​         ​   €    28,164 
​                                                                                                           ​   ​       ​          ​   ​       ​          ​   ​              ​   ​   ​       ​       ​   ​       ​       ​   ​       ​         ​   ​    ​      
Cash out from acquisition of subsidiaries (payment of deferred consideration in 2023)                       ​   ​       ​          ​   ​       ​          ​   €          7,000   ​   ​       ​       ​   ​       ​       ​   ​       ​         ​   €    7,000  
​
​
​
​
​
29. Details of the NovAlix transaction
We completed the integrated drug discovery collaboration transaction with NovAliX on June 30, 2023, effective as from July 1, 2023. Under the terms of the agreement, our drug discovery and research activities conducted in Romainville, France, and our employees in Romainville, which are exclusively dedicated to the operation of these activities, were transferred to NovAliX who would assume all ongoing research and discovery activities in Romainville, and this for no consideration. In return, we were committed to utilizing the research capabilities and expertise of NovAliX through a five year-collaboration and within the context of the company’s R&D portfolio, resulting in a total commitment of €73.8 million on June 30, 2023 (€41.6 million on December 31, 2024).

F-55

The collaboration agreement and sale and purchase agreement were negotiated as a package with one single commercial objective and with an agreed consideration for the transaction as a whole.
The impact of the transfer of activities and personnel (reference is made to the table